User profiles for Mikail Dogan

Mikail Dogan

Post-doctoral Associate, The Jackson Laboratory for Genomic Medicine
Verified email at jax.org
Cited by 398

[HTML][HTML] SARS-CoV-2 specific antibody and neutralization assays reveal the wide range of the humoral immune response to virus

M Dogan, L Kozhaya, L Placek, C Gunter… - Communications …, 2021 - nature.com
Abstract Development of antibody protection during SARS-CoV-2 infection is a pressing
question for public health and for vaccine development. We developed highly sensitive SARS-…

Chemotherapeutics and CAR‐T cell‐based immunotherapeutics screening on a 3D bioprinted vascularized breast tumor model

M Dey, MH Kim, M Dogan, M Nagamine… - Advanced Functional …, 2022 - Wiley Online Library
Despite substantial advancements in development of cancer treatments, lack of standardized
and physiologically‐relevant in vitro testing platforms limit the early screening of anticancer …

A distal enhancer at risk locus 11q13.5 promotes suppression of colitis by Treg cells

…, CJ Imianowski, L Bossini-Castillo, FM Grant, M Dogan… - Nature, 2020 - nature.com
Genetic variations underlying susceptibility to complex autoimmune and allergic diseases are
concentrated within noncoding regulatory elements termed enhancers 1 . The functions of …

Engineering human MAIT cells with chimeric antigen receptors for cancer immunotherapy

M Dogan, E Karhan, L Kozhaya, L Placek… - The Journal of …, 2022 - journals.aai.org
Engineering immune cells with chimeric Ag receptors (CARs) is a promising technology in
cancer immunotherapy. Besides classical cytotoxic CD8+ T cells, innate cell types such as NK …

Biofabrication of 3D breast cancer models for dissecting the cytotoxic response of human T cells expressing engineered MAIT cell receptors

…, M Nagamine, E Karhan, L Kozhaya, M Dogan… - …, 2022 - iopscience.iop.org
Immunotherapy has revolutionized cancer treatment with the advent of advanced cell
engineering techniques aimed at targeted therapy with reduced systemic toxicity. However, …

Antibody responses to SARS-CoV-2 after infection or vaccination in children and young adults with inflammatory bowel disease

J Dailey, L Kozhaya, M Dogan… - Inflammatory bowel …, 2022 - academic.oup.com
Background Characterization of neutralization antibodies to SARS-CoV-2 infection or vaccination
in children and young adults with inflammatory bowel disease (IBD) receiving biologic …

Novel SARS-CoV-2 specific antibody and neutralization assays reveal wide range of humoral immune response during COVID-19

M Dogan, L Kozhaya, L Placek, CL Gunter, M Yigit… - MedRxiv, 2020 - medrxiv.org
Abstract Development of antibody protection during SARS-CoV-2 (CoV-2) infection is a
pressing question for public health and for vaccine development. We developed highly sensitive …

Functional interrogation of primary human T cells via CRISPR genetic editing

…, L Kozhaya, C Tastan, L Placek, M Dogan… - The Journal of …, 2018 - journals.aai.org
Developing precise and efficient gene editing approaches using CRISPR in primary human
T cell subsets would provide an effective tool in decoding their functions. Toward this goal, …

Targeting SARS‐CoV‐2 infection through CAR‐T‐like bispecific T cell engagers incorporating ACE2

M Dogan, L Kozhaya, L Placek… - Clinical & …, 2022 - Wiley Online Library
Objectives Despite advances in antibody treatments and vaccines, COVID‐19 caused by
SARS‐CoV‐2 infection remains a major health problem resulting in excessive morbidity and …

[HTML][HTML] STAT4 Phosphorylation of T-helper Cells predicts surgical outcomes in Refractory Chronic Rhinosinusitis

…, M Plassmeyer, L Kozhaya, D Loizou, M Dogan… - medRxiv, 2023 - ncbi.nlm.nih.gov
Objective: Chronic rhinosinusitis (CRS) impacts an estimated 5% to 15% of people worldwide,
incurring significant economic healthcare burden. There is a urgent need for the discovery …